The safety fears involve possible increased risk to people who had not previously been exposed to the dengue virus prior to vaccination with Dengvaxia. Dengvaxia, the first approved Dengue vaccine, had been forecast by Sanofi to eventually bring in nearly $1 billion in annual sales. The WHO, which issued a report identifying the vaccine's safety risk in mid-2016, recommended it only be used in people who had prior dengue infection. Sanofi spent 20 years developing the world's first dengue vaccine at a cost of around 1.5 billion euros ($1.78 billion). Consensus analyst forecasts collated by Thomson Reuters before the latest problems pointed to Dengvaxia sales of about 360 million euros ($426.5 million) by 2022.

Source: bd News24 December 04, 2017 22:07 UTC